O-22 A novel Artificial Neural Network based algorithm to analyse the interaction patterns existing in gene microarrays: An application to breast cancer genomic data  by Lemetre, Christophe et al.
Conclusion: Mean substitution and multiple imputation per-
formed equally well in dealing with missing data generated by
TMA. Complete case analysis, the usual default method for statis-
tical software, resulted in the least accurate and least precise esti-
mates. Given the ease of implementing MS or MI, either approach
should be preferred to CCA.
doi:10.1016/j.ejcsup.2010.06.020
O-20 RATES OF GROWTH OF BREAST CANCER
R.W. Blamey, G. Ball, I.O. Ellis. NottinghamCity Hospital, Nottingham,
UK
Many estimates of growth rate have been published, mostly
theoretical. Here 3 clinically based measurements have been used
to produce curves of growth from inception (one cell) to 7 cm
diameter for each grade.
1. Screening effect – In a trial of screening an excess of tumours
were screen diagnosed by the end of the trial period. Time for
excess to present was calculated as G3 3–6 months, G2 1–
2 years and G1 5–6 years. The mean sizes by method of detec-
tion allowed volume doubling times to be calculated.
2. Occult time for inception to diagnosis – In young women there
is an excess of G3’s and few G1’s. Assuming that inception by
age is constant, graphs of actual detection rates at each age
and of expected allows calculation of the times for which each
grade is occult.
3. Time from primary treatment to death from breast cancer –
Plotting times to death gives medians for G3 167 months, G2
98 and G1 50.
4. As tumours enlarge mitoses become concentrated in the outer
2 mm ‘shell’.1
5. These observations allow curves of volume to be drawn for
each grade from single cell inception from which cell doubling
is assumed, giving a curve increasing logarithmically. From
10 mm diameter growth begins to slow logarithmically with
cell doubling restricted to the outer shell.
Reference:
1. Connor AJM et al. Breast 1997;6:171–6.
doi:10.1016/j.ejcsup.2010.06.021
O-21 DETECTION AND QUANTIFICATION OF MicroRNAs IN
LASER MICRODISSECTED FORMALIN-FIXED PARAFFIN EMBED-
DED (FFPE) BREAST CANCER TISSUES
Sarkawt M. Khoshnaw a, Des G. Powe a, Jorge S. Reis-Filho b, Ian O.
Ellis a, Andrew R. Green a. aDepartment of Histopathology, University
of Nottingham and Nottingham University Hospitals, Nottingham,
UK. bBreakthrough Breast Cancer Research Centre, Institute of Cancer
Research, London, UK
MicroRNAs (miRNAs) are a class of endogenous non-coding
RNAs that target protein coding mRNAs for cleavage or transla-
tional repression. Both profiling and functional studies demon-
strate deranged miRNA expression in many human cancers
including breast tumours. Research in this field is increasing
and the potential of miRNAs for being used in clinical settings
emphasises the need for sensitive detection techniques.
In this study, techniques for the analysis of miRNA expression
in microdissected FFPE breast cancer tissues were developed and
optimised. Full face sections from three invasive breast tumour
samples and different microdissected areas (1000–10 million ll2)
and section thickness (10–20 ll) were analysed. Total RNA was
extracted using commercially available RNA extraction kits
(miRNeasy FFPE Kit, Qiagen; RecoverAlle Total Nucleic Acid Isola-
tion Kit for FFPE, Ambion; PureLink FFPE RNA Isolation Kit, Invit-
rogen). Three miRNAs (miR21: highly expressed, miR-29c:
intermediately expressed, and miR-127: low expression in breast
cancer) extracted from both gross and microdissected invasive
breast cancer tissues were quantified using real-time PCR.
The PureLink kit produced largest quantities of total RNA from
FFPE breast tumours. All three miRNA (21, 29c and 127) were suc-
cessfully detected by real-time PCR and levels of sensitivity were
comparable between extraction methods. Our data showed that
relative miRNA levels gradually decreased with diminishing
amounts of microdissected tissue used but reliable miRNA quan-
tification was obtained using at least 5 million ll2 from 20 ll thick
FFPE breast tissue sections.
In contrast to previously published results, quantity of miRNA
detected in breast tissue samples depends on the amount of tis-
sue used, and cannot be performed reliably from one or a few
cells.
doi:10.1016/j.ejcsup.2010.06.022
O-22 A NOVEL ARTIFICIAL NEURAL NETWORK BASED ALGO-
RITHM TO ANALYSE THE INTERACTION PATTERNS EXISTING IN
GENE MICROARRAYS: AN APPLICATION TO BREAST CANCER
GENOMIC DATA
Christophe Lemetre, Lee James Lancashire, Graham Roy Ball.
Nottingham Trent University, UK
Genomic array technologies, by allowing the assessment of
the level of expression of thousands of genes simultaneously in
the same experiment, have brought the hope to identify new bio-
markers related to particular outcome in disease. The majority of
the research conducted to date with gene microarrays has only
been focusing on this biomarker discovery. However, these arrays
hold the inherent information of gene co-expression patterns and
only few groups have focused their attention toward deciphering
such network of interactions and regulation.
We present here a novel approach based on Artificial Neural
Network technology to further analyse the data extracted from
gene array experiments. This approach has been applied to a
well-known breast cancer dataset publicly available.1 The results
showed interesting patterns of interactions or gene regulation,
and some of them could be confirmed by alternative methods,
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or previously published work. The algorithm has been subse-
quently further tested on a second cohort2 to assess the reproduc-
ibility of the approach.
References:
1. van’t Veer LJ et al. Gene expression profiling predicts clinical
outcome of breast cancer. Nature 2002;415:530–6.
2. van de Vijver MJ et al. A gene-expression signature as a
predictor of survival in breast cancer. N Engl J Med
2002;347:1999–2009.
doi:10.1016/j.ejcsup.2010.06.023
O-23 IMPRINTED GENE METHYLATION IN BLOOD AND RISK OF
BREAST CANCER
P. Haggarty, G. Hoad, P. Scott, L. Simpson, A. Samad, E. Smyth, S.D.
Heys. RINH, University of Aberdeen, Aberdeen, UK
Loss of imprinting is a common observation in tumours but it
is not known whether this results from other pathologies or
whether imprinting changes may predispose to disease. We set
out to determine whether women newly diagnosed with breast
cancer had altered imprinted gene methylation in non-tumour
tissue (blood cells) compared to women without the disease.
Over 1000 women – newly diagnosedwith breast cancer and dis-
ease free controls – were recruited at Aberdeen Breast Clinic. A
sample of 92 controls and 92 cases were matched for age, weight,
height, BMI and menopausal status. Multiple methylation sites
were measured in two imprinted genes (IGF2 and PEG3) in blood
DNA. Methylation was determined by pyrosequencing using a Qia-
gen PyroMark MD system after bisulphite conversion of DNA using
Epitect Bisulfite kits (Qiagen, Crawley, UK). Analysis of variancewas
carried out using STATA 11MP (Stata Corp, College Station, USA).
The mean population methylation level was 47.6 (SD 2.5)% for
PEG3 and 50.0 (SD 5.5)% for IGF2. Compared to controls, women
diagnosed with breast cancer had significantly different levels
of methylation in PEG3 (p < 0.001). IGF2 methylation was also dif-
ferent between groups but this was only approaching statistical
significance (p = 0.058). Methylation was not related to meno-
pausal status. These differences in normal tissue suggest that
altered imprinted gene methylation may precede the develop-
ment of the disease. They also point to early life programming
as a possible cause of breast cancer.
This study was funded by Breast Cancer Campaign (Project
2008MayPR46).
doi:10.1016/j.ejcsup.2010.06.024
O-24 INVESTIGATION OF BRCA1 AND BRCA2 UNCLASSIFIED
VARIANTS USING RNA STUDIES: EXPERIENCES AND INTEREST-
ING CASES FROM THE WEST MIDLANDS REGIONAL GENETICS
LABORATORY
Elizabeth Perrott, Pauline K. Rehal, Ana Maria Brasgoldberg,
Fiona Macdonald. West Midlands Regional Genetics Laboratory,
Birmingham, UK
A very successful high throughput screening strategy for the
BRCA1 and BRCA2 genes has now been established at the West
Midlands Regional Genetics laboratory (WMRGL) since 2006. How-
ever having resolved the problems of large backlogs and long
reporting times the challenge has now shifted to the prediction
of the functional consequence of variants of unknown clinical
significance which account for a significant proportion of
reported sequence alterations in BRCA1 and BRCA2.
Laboratory methods to identify which of these sequence vari-
ants are pathogenic mutations would have utility for counseling
and clinical decision making when identified in patients with a
family history of breast cancer.
The WMRGL currently undertakes RNA investigations on
unclassified sequence variants for several familial cancer disor-
ders for both local and external referrals. To date we have under-
taken analysis on 92 cases covering 13 different disorders
including non-cancers. RNA investigations specifically for BRCA1
or BRCA2 variants have been performed on 25 samples. An over-
view of the service will be presented together with results from
interesting cases highlighting the challenges faced in interpreta-
tion of this data.
doi:10.1016/j.ejcsup.2010.06.025
O-25 ER POSITIVE SCREEN DETECTED BREAST CANCERS (SDBC)
DO NOT REQUIRE CHEMOTHERAPY
N.J. Bundred a, J. Morris b, S. Cheung c, W.F. Knox d, G.M.
Lawrence c. aAcademic Department of Surgery, University Hospital of
South Manchester, UK. bAcademic Department of Statistics, University
Hospital of South Manchester, UK. cWest Midlands Cancer Intelligence
Unit, Birmingham, UK. dAcademic Department of Pathology, University
Hospital of South Manchester, UK
Meta-analysis of symptomatic breast cancer trials advises
chemotherapy to women <70 years of age at high risk of death
(i.e. benefit of >1% survival benefit from treatment) but UK screen
detected breast cancers (SDBC) (aged 50–65 years) have an overall
97.2% 5 year relative survival compared to 77.6% for symptomatic
cancers. Guidelines recommend chemotherapy for all cancers
>10 mm in size (i.e. 35% SDBC) whereas in 2001/2 only 23% SDBC
in the UK received chemotherapy.
To determine which women benefit from chemotherapy, we
analysed 1681 symptomatic and SDBC in Manchester. SDBC had
a lower risk of relapse with 5 year cancer mortality for oestro-
gen receptor (ER) positive cancers being low in the Excellent
(0%), Good (GPG) (1%) and Moderate Prognostic Group 1
(MPG1) (4%) but higher in the symptomatic GPG (4.1%) and
MPG1 (15.5%) (p 6 0.001). The ABS at BASO Audit 2001/2 indi-
cates 5 year survival improvements in the Moderate Prognostic
Group 2 (MPG2) and the Poor Prognostic Group (PPG) for SDBC
since 1990.
ER positive SDBC had a <0.6% mortality annually whereas the
symptomatic cancers had a 5% annual mortality in the first
5 years. ER positive SDBCs represent a group with a low risk of
relapse, not requiring chemotherapy. Improvements in survival
of SDBC relate to better treatment of ER negative and HER2
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